Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3

A differential quantitative protein expression study, comparing matched prostate cancerous and benign tissues from 31 patients, revealed proteins newly associated with prostate cancer. Average effects for 17 proteins whose abundance was significantly different (p<0.01) across patients ranged from 1.5‐ to 6.1‐fold, and included a number of known cancer markers. The most differentially abundant proteins between cancer and benign samples were isopeptidase T, serum amyloid P (SAP), annexin A3 (ANXA3) and mitochondrial enoyl coenzyme‐A hydratase. SAP is restricted to stroma in healthy tissue, and the lower abundance in tumours may be explained by the reduced stromal content. ANXA3 is present in healthy epithelial cells, exhibits strong staining in precancerous prostatic intraepithelial neoplasia, and is relatively less abundant in individual tumour cells of increasing Gleason pattern (GP), despite exhibiting higher overall tissue abundance in tumours. ANXA3 staining was predominantly cytoplasmic, yet nuclear localization was also observed. Strongly staining single cells, possibly phagocytes, were interspersed in highly dedifferentiated GP5 tumour areas among tumour cells without measurable ANXA3. Local recurrent androgen ablation therapy‐resistant tumours exhibit heterogenous low levels of ANXA3 staining. Results are discussed focussing on the potential implications for tumour tissues.

[1]  J. Casal,et al.  Proteomics-based Validation of Genomic Data , 2006, Molecular & Cellular Proteomics.

[2]  T. Fehm,et al.  Breast cancer proteomics by laser capture microdissection, sample pooling, 54‐cm IPG IEF, and differential iodine radioisotope detection , 2006, Electrophoresis.

[3]  H. Kiyama,et al.  Annexin III implicated in the microglial response to motor nerve injury , 2006, Glia.

[4]  Sung Goo Park,et al.  Annexin A3 is a potential angiogenic mediator. , 2005, Biochemical and biophysical research communications.

[5]  R. Burgemeister,et al.  Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. , 2005, Journal of proteome research.

[6]  Alexandre Pelzer,et al.  Small G‐protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis , 2005, The Prostate.

[7]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[8]  T. Hayakawa,et al.  Expression of annexin A3 in primary cultured parenchymal rat hepatocytes and inhibition of DNA synthesis by suppression of annexin A3 expression using RNA interference. , 2005, Biological & pharmaceutical bulletin.

[9]  Daniel J. Klionsky,et al.  Autophagy in Health and Disease: A Double-Edged Sword , 2004, Science.

[10]  T. Hayakawa,et al.  Isolated small rat hepatocytes express both annexin III and terminal differentiated hepatocyte markers, tyrosine aminotransferase and tryptophan oxygenase, at the mRNA level. , 2004, Biological & pharmaceutical bulletin.

[11]  Y. Hu,et al.  Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes. , 2004, International journal of oncology.

[12]  G. Ronquist,et al.  Dominant prostasome immunogens for sperm-agglutinating autoantibodies of infertile men. , 2004, Journal of andrology.

[13]  Rong-Fong Shen,et al.  Identification and proteomic profiling of exosomes in human urine. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Iizuka,et al.  Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus , 2004, Proteomics.

[15]  H. Klocker,et al.  Screening for prostate cancer: Updated experience from the Tyrol study , 2004, Current urology reports.

[16]  Hanno Langen,et al.  How Industry Is Approaching the Search for New Diagnostic Markers and Biomarkers* , 2004, Molecular & Cellular Proteomics.

[17]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[18]  Usha Menon,et al.  Progress and Challenges in Screening for Early Detection of Ovarian Cancer* , 2004, Molecular & Cellular Proteomics.

[19]  E. Petricoin,et al.  Proteomic approaches in cancer risk and response assessment. , 2004, Trends in molecular medicine.

[20]  H. Parnes,et al.  Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio. , 2004, The Journal of urology.

[21]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Eastham.  Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer , 2004, Expert opinion on investigational drugs.

[23]  G. Arienti,et al.  Role of human prostasomes in the activation of spermatozoa , 2004, Journal of cellular and molecular medicine.

[24]  Arul M Chinnaiyan,et al.  Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. , 2003, Urology.

[25]  D. Berg,et al.  14-3-3 proteins in the nervous system , 2003, Nature Reviews Neuroscience.

[26]  P. Febbo,et al.  Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.

[27]  M. Cahill,et al.  Protein abundance quantification in embryonic stem cells using incomplete metabolic labelling with 15N amino acids, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, and analysis of relative isotopologue abundances of peptides. , 2003, Rapid communications in mass spectrometry : RCM.

[28]  G. Schwall,et al.  Analysis of relative isotopologue abundances for quantitative profiling of complex protein mixtures labelled with the acrylamide/D3-acrylamide alkylation tag system. , 2003, Rapid communications in mass spectrometry : RCM.

[29]  P. Rudland,et al.  High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity , 2003, Oncogene.

[30]  J. Schaper,et al.  Myocytes Die by Multiple Mechanisms in Failing Human Hearts , 2003, Circulation research.

[31]  R.-Y. Yang,et al.  Galectins in cell growth and apoptosis , 2003, Cellular and Molecular Life Sciences CMLS.

[32]  Hung‐wen Liu,et al.  Enoyl-CoA hydratase. reaction, mechanism, and inhibition. , 2003, Bioorganic & medicinal chemistry.

[33]  C. Mold,et al.  Serum Amyloid P Component and C-Reactive Protein Opsonize Apoptotic Cells for Phagocytosis through Fcγ Receptors , 2002 .

[34]  L. Zitvogel,et al.  From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. , 2002, Current opinion in molecular therapeutics.

[35]  J. Moul,et al.  Molecular markers in prostate cancer: the role in preoperative staging. , 2002, Clinical prostate cancer.

[36]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[37]  S. Moss,et al.  Annexins: from structure to function. , 2002, Physiological reviews.

[38]  E. Petricoin,et al.  Proteomic analysis of human prostate cancer † , 2002, Molecular carcinogenesis.

[39]  C. Scharf,et al.  Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. , 2001, European journal of biochemistry.

[40]  F. Fitzpatrick,et al.  Cyclopentenone Prostaglandins of the J Series Inhibit the Ubiquitin Isopeptidase Activity of the Proteasome Pathway* , 2001, The Journal of Biological Chemistry.

[41]  P. Ricciardi-Castagnoli,et al.  Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles1 , 2001, The Journal of Immunology.

[42]  H. Jörnvall,et al.  Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry , 2001, Cellular and Molecular Life Sciences CMLS.

[43]  M. Vingron,et al.  Improved sensitivity proteomics by postharvest alkylation and radioactive labeling of proteins , 2000, Electrophoresis.

[44]  A. Partin,et al.  Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4‐216) recognizes nucleophosmin/B23 , 1999, The Prostate.

[45]  M. Haddad,et al.  Prostate secretory protein (PSP94) suppresses the growth of androgen‐independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis , 1999, The Prostate.

[46]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[47]  I. Maridonneau-Parini,et al.  Differential expression of two forms of annexin 3 in human neutrophils and monocytes and along their differentiation. , 1992, Biochemical and biophysical research communications.

[48]  N. Davidson.  Biology of breast cancer , 1991, Current Opinion in Oncology.

[49]  Massimo Loda,et al.  Fatty acid synthase: A metabolic oncogene in prostate cancer? , 2004, Journal of cellular biochemistry.

[50]  D. Nebert,et al.  Pharmacogenomics and “Individualized Drug Therapy” , 2003 .

[51]  C. Kallenberg,et al.  Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. , 2003, Arthritis and rheumatism.

[52]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.